Monoclonal Anti-FMC63 Antibody, Mouse IgG1 (Y45) (Carrier-free) (recommended for ADA assay)

DMF
製品番号/仕様
価格
Availability
数量
FM3-Y45A1-25ug
$815.00
In Stock - Delivery in 2-3 business days
FM3-Y45A1-100ug
$2,345.00
In Stock - Delivery in 2-3 business days
FM3-Y45A1-1mg (500ug X 2)
$8,995.00
In Stock - Delivery in 2-3 business days
FM3-Y45A1
製品金額 :
$ 0
推奨新製品 Request Quote
Contact Us
Contact Us
製品金額:
$ 0
  • 製品詳細
  • データ表示
  • Reviews & Citations
  • Important Statement
  • Resources
Source

Chimeric Monoclonal Anti-FMC63 Antibody, Mouse IgG1 (Y45) is recombinantly expressed in HEK293. It consists of mouse variable regions genetically fused to mouse IgG1 constant domains.

Antibody Type

Recombinant Monoclonal

Clone

Y45

Isotype

Mouse IgG1, Kappa

Host Species

Mouse

Reactivity

Human

Immunogen

FMC63

Specificity

Specifically recognizes the antigen-recognition domain of FMC63 derived antibody.

Application
Application
Recommended Use / Performance
ELISA
0.2-2 μg/mL
Purification

Protein A purified.

Aggregation

Less than 5%, as determined by SEC-MALS.

Concentration

Please refer to the Certificate of Analysis (CoA).

Form

Lyophilized

Formulation

Lyophilized from a 0.22 μm-filtered solution in PBS (pH 7.4), with trehalose as protectant.

Please contact us for customized product forms or formulations.

Reconstitution

Please refer to the Certificate of Analysis (CoA) for specific instructions.

Shipping

Lyophilized product is shipped at ambient temperature.

Storage

For long term storage, the product should be stored in a lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:
  • -20°C to -70°C for 12 months in lyophilized state;
  • -70°C for 6 months under sterile conditions after reconstitution.
Notices

Product Specific Notices: For research use only.

バックグランド

FMC63 is an IgG2a mouse monoclonal antibody specific for CD19, which is a target for the immunotherapy of B lineage leukaemias and lymphomas. FMC63 scFv is the most commonly used ectodomain component of CD19-specific CARs. So far, most of reported CART19 trials contain the anti-CD19 scFv derived from FMC63, including the two FDA-approved CARs Kymriah and Yescarta.